Abstract Library

#4216 Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer

Introduction: Galectin-3 (Gal-3) is a beta-galactoside involved in multiple biological and pathological processes including growth and differentiation, cellular adhesion and transformation, and metastatic potential.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Giampietro A, Lugli F, Maratta M,

Keywords: Thyroid, MTC, Galectine3,

#3670 Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas – A systematic review and meta-analysis

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC has shown efficacy in the metastatic setting of pheochromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.

Conference:

Presenting Author: Marretta A

Authors: Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O,

Keywords: PRRT, Pheochromocytoma, Paraganglioma, Neuroendocrine Tumor, Meta-analysis,

#3632 Medullary thyroid carcinoma and somatostatin analogues, a possible therapeutic choice in asymptomatic and slow radiological progression metastatic recurrent disease after surgery – Case report of a 22-years long term survival patient

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor of the thyroid and accounts for 1%-2% of thyroid cancers in the United States. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10%-15% at diagnosis. Treatment options for recurrent or progressive disease according to RECIST 1.1 criteria, are limited. Tyrosine kinase-inhibitors (TKI) are preferred as first-line systemic therapy. Although somatostatin analogues (SSA) may play a role in MTC, limited evidence is available.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Maratta M, Giampietro A, de Marinis L,

Keywords: medullary thyroid carcinoma (MTC), somatostatin analogues, survival,

#3476 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

Introduction: Second-line treatment for neuroendocrine carcinoma (NEC) have been investigated in prospective trials, with only few prospective trials ongoing. Therefore, there is no consensus on the second-line regimen to use in patients with progressive NEC. These patients have generally a poor performance status (PS) and the tolerance to combination therapy is low. Metronomic temozolomide showed, in retrospective trials, a good safety and efficacy profile.

Conference:

Presenting Author:

Authors: Cannella L, von Arx C, Bracigliano A, Pizzolorusso A, Antonella D,

Keywords: neuroendocrine, temozolomide, NEC, Treatment,

#3373 Educational learning investigational observational study (ELIOS): A 10-year Italian network to standardize procedures and obtain multicentric clinical research studies

Introduction: Neuroendocrine neoplasms (NEN) are heterogeneous tumors with peculiar biology and rising incidence. Multidisciplinary approach in skilled centers is required to manage these patients. Accurate and complete data are indispensable for high quality epidemiological and clinical research.

Conference:

Presenting Author:

Authors: Modica R, Tafuto S, Riccardi F, Di Sarno A, Rodriquenz M,

Keywords: neuroendocrine, research, network,